# B-Secur

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/b-secur

- Industry: Software
- Headquarters: Belfast, UK
- Website: www.b-secur.com
- Total disclosed funding: $8.3M
- Latest round: Series B (Jun 29, 2017)
- Investors on record: 5

## About

B-Secur Limited, based in the UK, specializes in advanced cardiac monitoring solutions, delivering innovative technology for healthcare providers to enhance patient care.Founded in 2014 and headquartered in Belfast, UK, B-Secur Limited focuses on ECG analytics and rhythm detection. The company has received a total of GBP 8.8 million across multiple funding rounds, with the most recent being led by First Capital Ventures in October 2021. CEO Alan Foreman has guided the company through its growth, emphasizing its commitment to technological integration in healthcare.B-Secur specializes in advanced cardiac monitoring solutions, with its core offering being the HeartKey® Rhythm solution. This FDA-cleared product is a universal ECG analytics software library designed for precise rhythm detection and analysis, enhancing diagnostic accuracy and operational efficiency for healthcare providers. The HeartKey® suite utilizes sophisticated ECG algorithms that improve signal clarity while minimizing signal noise, which ultimately supports clinicians in delivering actionable wellness insights to patients. The primary users of these products include healthcare providers, hospitals, and telehealth services, which leverage these tools for improved patient care. B-Secur's solutions are marketed globally, targeting regions where there is a growing demand for innovative cardiac monitoring technologies, including North America, Europe, and parts of Asia.B-Secur generates revenue through a combination of subscription-based models and partnerships with healthcare organizations. The structure of these transactions typically involves licensing agreements for the use of the HeartKey® Rhythm software, enabling healthcare providers to integrate this technology into their existing systems. In addition to software licensing, B-Secur may engage in direct B2B sales where hospitals and clinics acquire the technology for their cardiac care departments. The pricing plans reflect the value provided by their flagship HeartKey® product, which enhances clinical workflows and patient outcomes. Revenue is derived from both initial sales and ongoing support services, ensuring that clients receive continuous updates and technical assistance.B-Secur Limited will utilize the GBP 8.8 million raised in October 2021 to accelerate the commercial expansion of its technology within the consumer and medical industries, particularly in the US market. The company aims to develop and launch new products that enhance its existing offerings, with a focus on catering to the growing demand for cardiac monitoring solutions. This strategic expansion is expected to further solidify B-Secur's presence in new geographic regions and capitalize on increasing opportunities in the healthcare sector.

## Funding rounds

- Series B, Jun 29, 2017, $4.5M — Kernel Capital, Woodford Patient Capital Trust, Accelerated Digital Ventures
- Seed, Mar 1, 2015, $3.8M — Wharton Asset Management, Rudolf Wolff Limited

## Investors

- Wharton Asset Management — Seed
- Rudolf Wolff Limited (https://capitalatlas.ai/funds/rudolf-wolff-limited) — Seed
- Kernel Capital (https://capitalatlas.ai/funds/kernel-capital) — Series B
- Woodford Patient Capital Trust — Series B
- Accelerated Digital Ventures (https://capitalatlas.ai/funds/accelerated-digital-ventures) — Series B